To assess the frequency of TP53 alterations and their correlation with other genetic changes and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed integrative analysis using TP53 mutational screening and array-based genomic profiling in 234 CK-AML. TP53 mutations were found in 141/234 (60%) and TP53 losses were identified in 94/234 (40%) CK-AML; in total, 164/234 (70%) cases had TP53 alterations. TP53-altered CK-AML were characterized by a higher degree of genomic complexity (aberrations per case, 14.30 vs. 6.16; P<.0001), and by a higher frequency of specific copy number alterations, such as -5/5q-, -7/7q-, -16/16q-, -18/18q-, +1/+1p, and +11/+11q/amp11q13~25; among CK-AML, TP53-altered more frequently exhibited a monosomal karyotype (MK).
INTRODUCTION
Chromosomal abnormalities are found in about 55% of adult patients with acute myeloid leukemia (AML) and are among the most important independent prognostic factors(1-3). AML exhibiting three or more acquired chromosome aberrations in the absence of chromosomal rearrangements listed in the World Health Organization (WHO) 2008 category "AML with recurrent genetic abnormalities" are now defined as AML with complex karyotype (CK-AML) (1, 2) . CK-AML account for 10% to 15 % of adult AML, and the frequency increases with age. CK-AML belong to the cytogenetic adverse-risk group, since they are associated with very poor outcome when treated with intensive or non-intensive conventional chemotherapy (1, 3, 4) . Recently, a new cytogenetic category was introduced, that is, the monosomal karyotype (MK) defined by the presence of one single autosomal monosomy in association with at least one additional autosomal monosomy or one structural chromosomal abnormality (in the absence of core-binding-factor AML and acute promyelocytic leukemia) (5) . This MK category was reported to be associated with a dismal prognosis and to add prognostic information even in CK-AML.
Complex karyotypes often contain numerous chromosome aberrations that can only be partially or not at all interpreted using standard cytogenetic techniques. Such aberrations include unbalanced translocations with chromosomal material of unknown origin, marker or ring chromosomes, homogeneously staining regions or double minutes, the latter representing cytogenetic equivalents of high-level DNA amplifications. In general, CK-AML are characterized by chromosomal gains and losses, rather than balanced translocations suggesting distinct mechanisms in leukemogenesis (6) .
In recent years, molecular cytogenetic and array-based techniques have enabled a more precise characterization of these complex genetic changes. The imbalances most frequently found are losses affecting chromosome 5 or 5q (-5/5q-), -17/17p-, -7/7q-, -18/18q-, -16/16q-, -12/12p-, and gains affecting chromosome 8 or 8q (+8/+8q), +11/+11q, +21/+21q, +22/+22q, and +1/+1p (7) . Furthermore, novel potential target genes have been delineated based on the observation that they are located in critical regions of deletions (8) and ERG in 21q22 (7, (9) (10) (11) (12) .
One target located in the commonly deleted region of 17p13 is the tumor suppressor gene TP53. In AML, TP53 alterations (mutations and/or losses, TP53 altered ) are rare and have been closely associated with CK-AML (13) (14) (15) (16) . Clinically, TP53 alterations appear to be associated with inferior outcome (15) (16) (17) . However, these data are based on a small number of studies, and only one of these addressed both TP53 losses and mutations, but not the prognostic significance (15) .
The objectives of our study were (1) to study a large cohort of CK-AML (n=234) for 
PATIENTS AND METHODS

Patients
Peripheral blood (PB) and/or bone marrow (BM) samples from 234 adult patients with CK-AML were analyzed. The definition of CK-AML followed recommended criteria (1, 2) . The diagnosis of AML was based on French-American-British Cooperative Group criteria (18) , and after 2004 on WHO criteria (19) . One-hundred and thirty-three patients had de novo AML, 31 secondary AML (s-AML) following myelodysplastic syndrome or myeloproliferative neoplasms, 30 therapy-related (t-AML), and in 40 patients it was unknown. Of these 234 patients, 155 (66%) were treated on consecutive multicenter treatment trials of the GermanAustrian AML Study Group (AMLSG) applying age-adjusted intensive chemotherapy: AML HD93 (n=1) (20) , AML HD98A (n=30) (21) , and AMLSG 07-04 (n=54; NCT00151242) for younger patients (16 to 60 years); AML HD98B (n=27) (22) and AMLSG 06-04 (n=43; NCT00151255) for elderly patients (>60 years). All trials were approved by the local ethics committees of all participating institutions; all patients gave informed consent for treatment, cryopreservation of samples, and molecular analyses according to the Declaration of Helsinki. Samples were primarily selected based on availability of sufficient material for genomic profiling and mutational analysis.
Cytogenetic and molecular genetic analysis
For cytogenetic classification, metaphases of sufficient quality could be studied by chromosome banding analysis in 219 patients; karyotypes were described according to the International System for Human Cytogenetic Nomenclature(23).
Due to evolving technology that occurred in the course of the study, we switched from array-CGH-to single-nucleotide polymorphism (SNP) array-based genomic profiling. Array-CGH (n=131) using the 2.8k-platform and/or the 8.0k-platform and unpaired SNP analyses using Affymetrix GeneChip Human Mapping 250K Array (n=61) were performed as previously described (7, 24) ; Genome-Wide Human SNP Array 6.0 profiling (n=42) was For personal use only. on September 14, 2017. by guest www.bloodjournal.org From performed according to the manufacturer`s protocols (Affymetrix, Santa Clara, CA).
Genotyping console version 2.0 (Affymetrix) was used for analysis of 6.0 arrays. Microarray data will be available at gene expression omnibus at http://www.ncbi.nlm.nih.gov/geo/ (GEO accession number GSE34542).
TP53 sequence analysis
To identify mutations in exons 4 to 10 of TP53, denaturating high-performance liquid chromatography (DHPLC) was performed as previously described (25) . Aberrant profiles were verified by bidirectional sequencing and compared with wildtype sequence (GenBank; X54156). Mutations were described using two different databases (IARC TP53 Database; p53.iarc.fr and The TP53 Web Site; p53.free.fr) (26, 27) . Subcloning analyses using the TOPO ® TA Cloning ® Kit and resequencing were performed according to manufacturer`s protocols (Invitrogen, Carlsbad, CA).
Statistical analyses
The section on statistical analyses is provided in the Supplementary Information. 
RESULTS
TP53 mutation analysis
In 141 of the 234 (60%) patients with CK-AML, a total of 168 mutations were identified; 161 (96%) were located in the sequence-specific DNA-binding domain of p53
(residues 102-292). The vast majority were missense mutations (n=130), followed by deletions/insertions (n=21) [ 
Copy number alterations (CNAs) and copy number neutral loss of heterozygosity (uniparental disomy, UPD)
In the entire cohort of 234 CK-AML, genomic losses (n=1.845) were more frequent than gains (n=778) or high-level DNA amplifications (n=153). The median number of aberrations per case was 10 (range, 0-51); median numbers of losses, gains, and amplifications per case were 6 (range, 0-43), 2 (range, 0-28), and 0 (range, 0-7), respectively.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Recurrent losses were identified for the following chromosomes: monosomy 5 or losses of 5q (-5/5q-) (n=147; 63%), -7/7q-(n=123; 53%), -17/17p-(n=106; 45%), -16/16q-(n=66; 28%), -18/18q-, -12/12p-(n=65 each; 28%), -20/20q-(n=55; 24%), -3/3p-(n=54; 23%), and -11/11q-(n=35; 15%). Most frequent gains were +8/+8q (n=67; 29%), +11/+11q (n=61; 26%), +21/+21q (n=39; 17%), +1/+1p (n=37; 16%), +22/+22q (n=33; 14%), +13/+13q (n=29; 12%), +9/+9p (n=28; 12%), and +19/+19p (n=25; 11%). Most frequent high-level DNA amplifications mapped to 21q22, 11q13~25 (n=22 each; 9%), and 8q24 (n=8; 4%).
Usually large, but also submicroscopic losses (down to 800 kb in size) affecting the 
TP53
altered CK-AML had biallelic TP53 inactivation (not taken into account the 4 patients with potentially compound heterozygous TP53 mutations). Patient 96 exhibited a homozygous missense mutation in exon 6 (p.R213L) and an additional heterozygous frame shift mutation in exon 4 (p.A74fs) suggesting that these had occurred sequentially, with p.R213L being the primary event followed by UPD(17p) resulting in the homozygous mutation pattern, whereas the p.A74fs mutation followed the recombination event (Supplementary Figure 1) .
Correlation of TP53 alteration with pattern of chromosome abnormalities and CNAs
We correlated TP53 alterations, as assessed by DNA sequence analysis and arrayprofiling, with the pattern of chromosome abnormalities as identified by conventional cytogenetics, and with the pattern of CNAs as detected by array-based analyses (Table 1) . Figure 2 ).
Correlation of TP53 alterations with monosomal karyotype (MK)
By conventional cytogenetics, 171/219 (78%) CK-AML fulfilled the MK criteria (CK+/MK+ AML) as previously defined (5) . TP53 alterations were found in 137/171 (80%) 
P<.0001).
We subsequently determined MK+ AML based on array data (molMK). The frequency of CK+/molMK+ AML was much lower [75/234 (32%)], due to the fact that many monosomies described in chromosome banding analysis were not real monosomies, but part of chromosomal material hidden in unbalanced translocation or marker chromosomes. TP53 alterations were found in 59/75 (79%) CK+/molMK+ AML, and in 105/159 (66%) CK+/molMK-AML (P=.07) ( Table 1) .
Correlation of TP53 alterations with clinical characteristics, response to therapy, and survival
Analyses were restricted to patients enrolled into AMLSG multicenter treatment trials applying age-adjusted intensive chemotherapy [n=155, median age: 59 years (range 18-81)].
Since there were no significant differences regarding clinical characteristics, response to therapy, and survival for TP53 monoallelic altered and TP53 biallelic altered CK-AML (see Supplementary 
DISCUSSION
In our series of 234 CK-AML, TP53 was deleted and/or mutated in 70% of cases, thus representing the most frequently known altered gene in this AML subgroup. TP53 alterations were associated with older age, genomic complexity, specific chromosome abnormalities, monosomal karyotype, specific CNAs, and predicted for dismal outcome.
Loss of TP53 was found in about 40% of CK-AML by array-based techniques, a figure that corresponded well to that of 17p abnormalities found on chromosome banding analysis.
By DNA sequence analysis, 60% of cases exhibited TP53 mutations, consistent with previous reports (6, 15, 16) . Of note, at least two-thirds of mutated cases had biallelic TP53 alteration resulting from hemizygous mutations, compound heterozygous, and from homozygous mutations commonly as a result of homologous recombination leading to UPD.
Thus, when assessing for TP53 mutational status in CK-AML, it will be necessary to include DNA sequence analysis.
TP53
altered CK-AML were characterized by a significantly higher degree of genomic complexity, as assessed by total number of genomic losses and gains, as well as the frequency of high-level DNA amplifications. This observation fits well into the p53 pathomechanism of genomic instability (29) (30) (31) (32) (33) (34) (35) . TP53 altered CK-AML were also associated with specific abnormalities. As previously reported (15, 16, 36, 37) , -5/5q-and/or -7/7q-were significantly more frequent among TP53 altered CK-AML. Since we also applied array-based techniques, we identified additional CNAs associated with TP53 altered CK-AML, that is, -3/3p-, Recently, the cytogenetic category of "monosomal karyotype" was described allowing further risk stratification of CK-AML patients(5). Of note, in our study CK+/MK+ AML were significantly associated with TP53 alterations, found in 80% of CK+/MK+ AML compared with only 42% in CK+/MK-AML. Thus, TP53 alterations appear to be one molecular basis for this purely descriptive cytogenetic subset. The association of TP53 alterations with CK+/MK+ For personal use only. on September 14, 2017. by guest www.bloodjournal.org From AML was lost when TP53 alterations were correlated with CNAs identified by array-based assays. Not unexpectedly, many monosomies described in chromosome banding analysis were not real monosomies, but were part of chromosomal material hidden in unbalanced translocations or marker chromosomes.
Little is known about the pathogenesis of CK-AML, but the high frequency of TP53 alteration, and in particular biallelic alteration, suggests an important role of p53 in leukemogenesis. Evidence for this hypothesis comes from several observations in mice and human disease: (1) mouse studies requiring biallelic TP53 inactivation and a concomitant "second hit" for myeloid leukemogenesis (38, 39) demonstrated that p53 lost myeloid progenitors exhibit aberrant self-renewal, thereby promoting AML (40); (2) Besides being older and having lower BM blasts, TP53 altered CK-AML had no distinct clinical phenotype, possibly due to the complexity of concurrent genetic events and to different consequences of TP53 alterations. TP53 losses or mutations entail various tumor phenotypes (44) , and mouse models investigating TP53 inactivation identified gain-of-function for hot spot mutations, such as R175H, R248W, and R273H, as well as increased proliferation related to accelerated tumorigenesis and leukemogenesis resulting in a more aggressive AML (35, (44) (45) (46) .
p53 loss-of-function has been shown to be related to resistance to chemotherapy, also to cytarabine (46, 47) . Consistent with this finding, TP53 alterations in our study were associated with resistance to "3+7"-based induction chemotherapy (Tables 1 and 2 
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